Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy
被引:0
|
作者:
R. H. Enting
论文数: 0引用数: 0
h-index: 0
机构:Department of Neurology,
R. H. Enting
P. Portegies
论文数: 0引用数: 0
h-index: 0
机构:Department of Neurology,
P. Portegies
机构:
[1] Department of Neurology,
[2] Academic Medical Center H2-214,undefined
[3] Meibergdreef 9,undefined
[4] 1105 AZ,undefined
[5] Amsterdam,undefined
[6] The Netherlands e-mail: P.Portegies@amc.uva.nl Tel.: +31-20-5663842 Fax: +31-20-6971438,undefined
来源:
Journal of Neurology
|
2000年
/
247卷
关键词:
Key words Progressive multifocal leukoencephalopathy;
Anti-HIV agents;
Cytarabine;
HIV infection;
D O I:
暂无
中图分类号:
学科分类号:
摘要:
We assessed survival in AIDS-related progressive multifocal leukoencephalopathy (PML) and the effect of cytarabine and antiretroviral therapy in a retrospective analysis of a series of consecutive 35 patients with AIDS-related PML in an academic AIDS referral center over ¶15 years. Treatment regimens consisted of highly active antiretroviral treatment (HAART), intravenous cytarabine, or both. Median survival after diagnosis in the overall series was 88 days. Patients with low CD4 cell count tended to have shorter survival. Seven patients (20%) had prolonged survival (> 1 year). Cytarabine did not affect survival. Seven patients were treated with HAART, which did not significantly improve survival. We conclude that the prognosis of AIDS-related PML is still poor, with a median survival of ¶3 months.